Cytognomix has designed and developed targeted hybridization arrays with maximal coverage of complete unique gene sequences. The arrays not only cover known exons, but also include promoter, intronic, and downstream flanking genomic regions. This extensive coverage of regulatory regions is intended to produce companion data for our patented methods for interpreting non-coding variants of unknown significance. In addition to known single copy sequences, divergent repetitive elements, based on our patented ab initio technology (US Patents 7,734,424, 8,209,129, and 8,407,013), are incorporated in these enrichment products. The targeted results in the most comprehensive coverage available in the market. The company’s first capture array product is used for targeted sequencing of the inherited breast cancer genes: BRCA1, BRCA2, ATM, CDH1, CHEK2, PALB2, and TP53.
We have published a paper describing the ab initio sc probe technology:
Expanding probe repertoire and improving reproducibility in human genomic hybridization
Stephanie N. Dorman; Ben C. Shirley; Joan H. M. Knoll; Peter K. Rogan
Nucleic Acids Research 2013; doi: 10.1093/nar/gkt048